



## Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside

Guest Editors:

**Dr. Georg F. Weber**

Department of Surgery,  
University Hospital Erlangen,  
Friedrich-Alexander University  
Erlangen-Nuremberg, Erlangen,  
Germany

**Dr. Christoph Kahlert**

Department of Surgery, Carl  
Gustav Carus University Hospital  
Dresden, Technische Universität  
Dresden, Dresden, Germany

Deadline for manuscript  
submissions:

**closed (10 October 2022)**

### Message from the Guest Editors

Liquid biopsies are in the focus of current cancer research. Liquid biopsies are cancer byproducts (mainly circulating tumor cells (CTC), circulating tumor DNA (ctDNA), tumor exosomes, and tumor-educated blood platelets (TEPs)), easily accessible in blood and other body fluids, and may be foreseen as an alternative to tissue-based diagnostics, as well as gastroenterologic and radiologic screening methods. The use of liquid biopsies may lead to early detection of primary and recurrent cancer disease, to a better control of multidisciplinary therapy regimens and the early detection of therapeutic resistance.

In this Special Issue, we will offer an overview of the various types of liquid biopsies currently investigated in gastrointestinal cancer disease, focus on their possible use as novel diagnostic biomarkers, and highlight their importance as one of the main future research pillars in gastrointestinal cancer disease.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)